Crinetics Pharmaceuticals (CRNX) Stock Price, Quote, News & History

Comments

Crinetics Pharmaceuticals Inc (CRNX) Stock Price, Quote, News & History

CRNXNASDAQ

Trade with Public

$39.02

-0.75-1.89%

At close: Apr 15, 5:00 PM EST

$39.02

-0.75-1.89%

Pre-Market: 3:00 AM EST

OverviewNews Earnings Options Analyst Ratings Insider Trades Short Interest Government Trades Stock Report

Key Statistics

Open

-

Close

$39.02

Volume / Avg.

0 / 1.08M

Day Range

- - -

52 Wk Range

25.83 - 57.99

Market Cap

$4.00B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

52

Short Interest

17.62%

Days to Cover

11.91

Recent Crinetics Pharmaceuticals Inc News

Crinetics Experimental Pill Slashes Hormones In Rare Adrenal Disease Trial

Crinetics Pharmaceuticals reported positive topline results from Phase 2 studies of atumelnant for CAH and ACTH-dependent Cushing's syndrome.

Vandana Singh

FDA Approves Crinetics Pharma's First Daily Pill For Rare Growth Disorder

On Thursday, the U.S.

Vandana Singh

Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly

Crinetics shares PATHFNDR trial data showing oral Palsonify maintained hormone and symptom control in acromegaly patients over 84–96 weeks.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-377.92M

Investing Cash Flow (TTM)

173.91M

Financing Cash Flow (TTM)

40.61M

Free Cash Flow (TTM)

-383.68M

Capital Expenditure (TTM)

-5.76M

Net Change in Cash (TTM)

-163.40M

Analyst Trends and Forecast

0

Nov 25

2

Jan

0

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$3.11B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

476.76

PB Ratio (TTM)

4.12

Earnings Yield % (TTM)

-12.69%

Earnings Yield % (FWD)

-13.69%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$9.48

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$101.54M

Debt to Equity

0.05

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$39.02

Volume / Avg.

0 / 1.08M

Day Range

- - -

52 Wk Range

25.83 - 57.99

Market Cap

$4.00B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

52

Short Interest

17.62%

Days to Cover

11.91

About

Sector

Health Care

Industry

Pharmaceuticals

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltu...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Crinetics Pharmaceuticals (CRNX) stock?

A

You can purchase shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Crinetics Pharmaceuticals (CRNX) competitors?

A

Other companies in Crinetics Pharmaceuticals’s space includes: Supernus Pharmaceuticals Inc (NASDAQ:SUPN), Tarsus Pharmaceuticals Inc (NASDAQ:TARS), Terns Pharmaceuticals Inc (NASDAQ:TERN), Axsome Therapeutics Inc (NASDAQ:AXSM) and Alumis Inc (NASDAQ:ALMS).

Q

What is the forecast, or price target, for Crinetics Pharmaceuticals (CRNX) stock?

A

Crinetics Pharmaceuticals has a consensus price target of $76.50.

Q

What is the current price for Crinetics Pharmaceuticals (CRNX)?

A

The stock price for Crinetics Pharmaceuticals (NASDAQ: CRNX) is $39.02 last updated April 16, 2026 at 4:00 PM EDT.

Q

Does Crinetics Pharmaceuticals (CRNX) pay a dividend?

A

There are no upcoming dividends for Crinetics Pharmaceuticals.

Q

When is Crinetics Pharmaceuticals (NASDAQ:CRNX) reporting earnings?

A

Crinetics Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Crinetics Pharmaceuticals (CRNX) going to split?

A

There is no upcoming split for Crinetics Pharmaceuticals.

Q

What sector and industry does Crinetics Pharmaceuticals (CRNX) operate in?

A

Crinetics Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

People Also Watch

Supernus Pharmaceuticals Inc

NASDAQ:SUPN

$49.22

%

Tarsus Pharmaceuticals Inc

NASDAQ:TARS

$67.72

%

Terns Pharmaceuticals Inc

NASDAQ:TERN

$52.68

-0.02%

Axsome Therapeutics Inc

Ligand Pharmaceuticals Inc

NASDAQ:LGND

$223.24

%

Jazz Pharmaceuticals PLC

NASDAQ:JAZZ

$197.83

%

Indivior Pharmaceuticals Inc

NASDAQ:INDV

$31.51

%

Key Statistics

Open

-

Close

$39.02

Volume / Avg.

0 / 1.08M

Day Range

- - -

52 Wk Range

25.83 - 57.99

Market Cap

$4.00B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

52

Short Interest

17.62%

Days to Cover

11.91

Recent Crinetics Pharmaceuticals Inc News

Crinetics Experimental Pill Slashes Hormones In Rare Adrenal Disease Trial

Crinetics Pharmaceuticals reported positive topline results from Phase 2 studies of atumelnant for CAH and ACTH-dependent Cushing's syndrome.

Vandana Singh

FDA Approves Crinetics Pharma's First Daily Pill For Rare Growth Disorder

On Thursday, the U.S.

Vandana Singh

Crinetics Reports Durable Symptom, Hormone Control With Oral Drug In Acromegaly

Crinetics shares PATHFNDR trial data showing oral Palsonify maintained hormone and symptom control in acromegaly patients over 84–96 weeks.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-377.92M

Investing Cash Flow (TTM)

173.91M

Financing Cash Flow (TTM)

40.61M

Free Cash Flow (TTM)

-383.68M

Capital Expenditure (TTM)

-5.76M

Net Change in Cash (TTM)

-163.40M

Analyst Trends and Forecast

0

Nov 25

2

Jan

0

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.4

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$3.11B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

476.76

PB Ratio (TTM)

4.12

Earnings Yield % (TTM)

-12.69%

Earnings Yield % (FWD)

-13.69%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$9.48

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$101.54M

Debt to Equity

0.05

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$39.02

Volume / Avg.

0 / 1.08M

Day Range

- - -

52 Wk Range

25.83 - 57.99

Market Cap

$4.00B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

52

Short Interest

17.62%

Days to Cover

11.91

About

Sector

Health Care

Industry

Pharmaceuticals

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltu...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry